WELLO2
18.5.2020 07:02:06 CEST | Business Wire | Press release
Training with a counter pressure steam breathing device has the potential to improve voice quality, as revealed in a recent pilot study in Finland. A report on the study was published in Journal of Voice, a peer-reviewed publication regarded as the world's premiere journal for voice medicine and research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200517005004/en/
The protocol of another study, now investigating benefits of using WellO2, a unique counter pressure steam breathing device, with patients with chronic obstructive pulmonary symptoms, has been approved by the ethical committee of the University of Tampere. Both studies focus on the effects of the combination of the inspiratory and expiratory muscle training with warm steam.
Voice professionals have found help
Even before the Finnish study came out, various renown voice professionals have been using WellO2 to help with their voice problems. Among the artists is Uriah Heep’s lead singer Bernie Shaw , who has warmly endorsed WellO2 (see link, below).
The aim of the Finnish pilot study was to determine the efficacy of the 4-week breathing exercise intervention on participants with voice symptoms. Six non-smoking women, mean age 49, experiencing voice symptoms made respiratory muscle exercises for a month with counter pressure on both inspiration and expiration and with warm steam. Speech samples were acoustically measured and perceptually analyzed using the GRBAS, the grade, roughness, breathiness, asthenia and strain scale. Afterwards, perceived voice symptoms and self-reported effort in breathing and phonation were analyzed.
Participants: Breathing was significantly less effortful
The total score of the Acoustic Voice Quality Index (AVQI) and some of its subcomponents, namely shimmer and harmonic-to-noise ratio, and the perceptually evaluated grade, roughness, and strain indicated significantly improved voice quality. However, neither the nature or frequency of the experienced voice symptoms nor the perceived phonatory effort changed as the function of intervention. According to the participants, their breathing was significantly less effortful after the intervention, although no significant changes were observed in the objective respiratory measurements with a spirometer.
According to the study, training with the WellO2 device has the potential to improve voice quality. However, the effects of using WellO2 need to be confirmed by further studies with a larger number of participants, the pilot study concluded.
New studies with WellO2 and chronic obstructive pulmonary symptoms
The ethical committee of the University of Tampere recently gave a positive statement for the clinical study of WellO2 with patients with chronic obstructive pulmonary symptoms. The team is testing the effect of WellO2 device for the respiratory muscle exercises that provides counter pressure. There are several hundreds of referred studies on steam inhalation and counter pressure breathing. None have found any severe side effects for using such devices.
Patented WellO2 counter pressure steam breathing device was developed by Hapella Oy, Finland. The device has been available since 2016 as a non-medical device. Over 35 000 devices have been sold in Finland, alone. It is sold both in pharmacies and other stores, like electric commodity store chain of Elgiganten in Sweden and Elkjøp in Norway. Wello2 is available on e-commerce, also at various Amazon e-stores, e.g. in Italy and Germany.
Medical references & links:
https://wello2.com/blogs/news/wello2-counter-pressure-steam-breathing-helps-with-voice-symptoms
View source version on businesswire.com: https://www.businesswire.com/news/home/20200517005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
